Evidence hub

Arterial Hypertension: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 35 registered records for Arterial Hypertension — 5 recruiting, 5 at Phase 3 or 4, in 13 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Resistant hypertension is a plumbing-and-signalling problem: vascular stiffness, renal sodium handling and sympathetic tone. Cell approaches are studied mostly for endothelial repair and inflammation, usually as an add-on to drugs rather than a replacement. Blood pressure is also the most placebo-responsive vital sign in medicine, which shapes how these trials must be designed.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC11208
HSCT5212
exosomes8205
PRP1000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 43% of country mentions among sampled studies; 13 countries host at least one site.

CountryStudies with a site there
United States13
China6
Brazil2
Canada2
Colombia2
Taiwan1
Mexico1
Russia1

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT03011541 — Stem Cell Ophthalmology Treatment Study IIn/aRecruiting500MD Stem Cells2016-01
NCT07157670 — Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.n/aNot Yet Recruiting400Assistance Publique - Hôpitaux de Paris2025-09-15
NCT01920867 — Stem Cell Ophthalmology Treatment Studyn/aUnknown300MD Stem Cells2012-08
NCT07613099 — Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT ImagingPhase 3Recruiting210National Heart, Lung, and Blood Institute (NHLBI)2026-09-02
NCT01155128 — Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney DiseasePhase 4Unknown200Federal University of Pelotas2011-09
NCT03562715 — microRNAs Role in Pre-eclampsia Diagnosisn/aCompleted200Cairo University2016-11-28

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT07613099 — Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imagingn/aRecruitingn/aNational Heart, Lung, and Blood Institute (NHLBI)2026-09-02
NCT07157670 — Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.n/aNot Yet Recruitingn/aAssistance Publique - Hôpitaux de Paris2025-09-15
NCT07119580 — Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoman/aRecruitingn/aNational Taiwan University Hospital2025-07-08
NCT06498440 — Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCTn/aUnknownn/aSt. Joseph's Healthcare Hamilton2024-09-01
NCT07183384 — MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunctionn/aRecruitingn/aUniversitas Padjadjaran2024-07-01

Reading this honestly

These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided. For Arterial Hypertension specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Arterial Hypertension?

35 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 5 were recruiting.

Which therapy class is furthest along for Arterial Hypertension?

Ranked by Phase 3/4 records: HSCT (1), MSC (0), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.